Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006));Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics

Cancer Cell

Volumn 29, Issue 2, 2016, Pages 145-158

  Lalaoui, Najoua ^a,b   Hänggi, Kay ^c   Brumatti, Gabriela ^a,b   Chau, Diep ^a,b   Nguyen, Nhu Y N ^d,e   Vasilikos, Lazaros ^c   Spilgies, Lisanne M ^c   Heckmann, Denise A ^a,b   Ma, Chunyan ^a,b   Ghisi, Margherita ^b,f   Salmon, Jessica M ^b,f   Matthews, Geoffrey M ^b,f   de Valle, Elisha ^e,g   Moujalled, Donia M ^d,e   Menon, Manoj B ^h   Spall, Sukhdeep Kaur ^a,b   Glaser, Stefan P ^a,b   Richmond, Jennifer ⁱ   Lock, Richard B ⁱ   Condon, Stephen M ^j   Gugasyan, Raffi ^e,g   Gaestel, Matthias ^h   Guthridge, Mark ^d,e   Johnstone, Ricky W ^b,f   Munoz, Lenka ^k   Wei, Andrew ^d,e   Ekert, Paul G ^a,b,l   Vaux, David L ^a,b   Wong, W Wei Lynn ^c   Silke, John ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g BURNET INSTITUTE   (Australia)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ University of New South Wales Sydney   (Australia)

^j TetraLogic Pharmaceuticals   (United States)

^k UNIVERSITY OF SYDNEY   (Australia)

^l ROYAL CHILDREN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; LY 2228820; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIABLO PROTEIN, HUMAN; MAP-KINASE-ACTIVATED KINASE 2; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; HUMAN; LEUKEMIA; MOLECULAR MIMICRY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MICE; MITOCHONDRIAL PROTEINS; MOLECULAR MIMICRY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958646766     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.08.009     Document Type: Erratum

References (53)

1. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
2. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18:6501-6504.
3. Bertrand M.J.M., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., Gillard J.W., Jaquith J.B., Morris S.J., Barker P.A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
4. Burnett A.K. New induction and postinduction strategies in acute myeloid leukemia. Curr. Opin. Hematol. 2012, 19:76-81.
5. Burnett A.K., Russell N.H., Hills R.K., Hunter A.E., Kjeldsen L., Yin J., Gibson B.E., Wheatley K., Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J. Clin. Oncol. 2013, 31:3360-3368.
6. Campbell R.M., Anderson B.D., Brooks N.A., Brooks H.B., Chan E.M., De Dios A., Gilmour R., Graff J.R., Jambrina E., Mader M., et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol. Cancer Ther. 2014, 13:364-374.
7. Carter B.Z., Mak P.Y., Mak D.H., Shi Y., Qiu Y., Bogenberger J.M., Mu H., Tibes R., Yao H., Coombes K.R., et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J. Natl. Cancer Inst. 2014, 106:djt440.
8. Cheung P.C., Campbell D.G., Nebreda A.R., Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J. 2003, 22:5793-5805.
9. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
10. Christofferson D.E., Li Y., Hitomi J., Zhou W., Upperman C., Zhu H., Gerber S.A., Gygi S., Yuan J. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis. 2012, 3:e320.
11. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 2009, 21:317-324.
12. Cohen P., Alessi D.R. Kinase drug discovery-what's next in the field?. ACS Chem. Biol. 2013, 8:96-104.
13. Condon S.M., Mitsuuchi Y., Deng Y., LaPorte M.G., Rippin S.R., Haimowitz T., Alexander M.D., Kumar P.T., Hendi M.S., Lee Y.H., et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 2014, 57:3666-3677.
14. Das M., Sabio G., Jiang F., Rincon M., Flavell R.A., Davis R.J. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 2009, 136:249-260.
15. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
16. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
17. Dumitru C.D., Ceci J.D., Tsatsanis C., Kontoyiannis D., Stamatakis K., Lin J.H., Patriotis C., Jenkins N.A., Copeland N.G., Kollias G., Tsichlis P.N. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000, 103:1071-1083.
18. Feoktistova M., Geserick P., Kellert B., Dimitrova D.P., Langlais C., Hupe M., Cain K., MacFarlane M., Hacker G., Leverkus M. cIAPs block Ripoptosome formation, a RIP1/caspase-containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 2011, 43:449-463.
19. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., Racevskis J., Dewald G.W., Ketterling R.P., Bennett J.M., et al. Anthracycline dose intensification in acute myeloid leukemia. New Eng. J. Med. 2009, 361:1249-1259.
20. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11:109-124.
21. Gaestel M., Kotlyarov A., Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discov. 2009, 8:480-499.
22. Gaither A., Porter D., Yao Y., Borawski J., Yang G., Donovan J., Sage D., Slisz J., Tran M., Straub C., et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 2007, 67:11493-11498.
23. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., Linch D.C., Medical Research Council Adult Leukaemia Working Party The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
24. Genovese M.C. Inhibition of p38: has the fat lady sung?. Arthritis Rheum. 2009, 60:317-320.
25. Gurgis F.M., Ziaziaris W., Munoz L. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Mol. Pharmacol. 2014, 85:345-356.
26. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-determines cellular necrotic response to TNF-alpha. Cell 2009, 137:1100-1111.
27. Kadia T.M., Kantarjian H., Kornblau S., Borthakur G., Faderl S., Freireich E.J., Luthra R., Garcia-Manero G., Pierce S., Cortes J., Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 2012, 118:5550-5559.
28. Knapp S., Arruda P., Blagg J., Burley S., Drewry D.H., Edwards A., Fabbro D., Gillespie P., Gray N.S., Kuster B., et al. A public-private partnership to unlock the untargeted kinome. Nat. Chem. Biol. 2013, 9:3-6.
29. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1999, 1:94-97.
30. Lawlor K.E., Khan N., Mildenhall A., Gerlic M., Croker B.A., D'Cruz A.A., Hall C., Kaur Spall S., Anderton H., Masters S.L., et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat. Commun. 2015, 6:6282.
31. Limberis M.P., Bell C.L., Wilson J.M. Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. Gene Ther. 2009, 16:441-447.
32. Luck S.C., Russ A.C., Botzenhardt U., Paschka P., Schlenk R.F., Dohner H., Fulda S., Dohner K., Bullinger L. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011, 25:1728-1738.
33. Micheau O., Lens S., Gaide O., Alevizopoulos K., Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 2001, 21:5299-5305.
34. Mourey R.J., Burnette B.L., Brustkern S.J., Daniels J.S., Hirsch J.L., Hood W.F., Meyers M.J., Mnich S.J., Pierce B.S., Saabye M.J., et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J. Pharmacol. Exp. Ther. 2010, 333:797-807.
35. Murphy J.M., Czabotar P.E., Hildebrand J.M., Lucet I.S., Zhang J.G., Alvarez-Diaz S., Lewis R., Lalaoui N., Metcalf D., Webb A.I., et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013, 39:443-453.
36. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., Harran P., Wang X. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
37. Ronkina N., Kotlyarov A., Dittrich-Breiholz O., Kracht M., Hitti E., Milarski K., Askew R., Marusic S., Lin L.L., Gaestel M., Telliez J.B. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 2007, 27:170-181.
38. Shakhov A.N., Collart M.A., Vassalli P., Nedospasov S.A., Jongeneel C.V. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 1990, 171:35-47.
39. Silke J., Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb. Perspect. Biol. 2013, 5. 10.1101/cshperspect.a008730.
40. Silke J., Vucic D. IAP family of cell death and signaling regulators. Methods Enzymol. 2014, 545:35-65.
41. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
42. Sun L., Wang H., Wang Z., He S., Chen S., Liao D., Wang L., Yan J., Liu W., Lei X., Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012, 148:213-227.
43. Tate C.M., Blosser W., Wyss L., Evans G., Xue Q., Pan Y., Stancato L. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J. Biol. Chem. 2013, 288:6743-6753.
44. Tenev T., Bianchi K., Darding M., Broemer M., Langlais C., Wallberg F., Zachariou A., Lopez J., Macfarlane M., Cain K., Meier P. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 2011, 43:1-18.
45. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., Vignali D.A., Bergsagel P.L., Karin M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 2008, 9:1364-1370.
46. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J.A., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNF alpha-dependent apoptosis. Cell 2007, 131:669-681.
47. Vince J.E., Wong W.W.-L., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., et al. IAP antagonists target cIAP1 to induce TNF alpha-dependent apoptosis. Cell 2007, 131:682-693.
48. Vince J.E., Wong W.W., Gentle I., Lawlor K.E., Allam R., O'Reilly L., Mason K., Gross O., Ma S., Guarda G., et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-activation. Immunity 2012, 36:215-227.
49. Volk A., Li J., Xin J., You D., Zhang J., Liu X., Xiao Y., Breslin P., Li Z., Wei W., et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J. Exp. Med. 2014, 211:1093-1108.
50. Wong W.W., Vince J.E., Lalaoui N., Lawlor K.E., Chau D., Bankovacki A., Anderton H., Metcalf D., O'Reilly L., Jost P.J., et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in a RIPK1 and RIPK3 dependent manner. Blood 2014, 123:2562-2572.
51. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., Shiba T., Yang X., Yeh W.C., Mak T.W., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
52. Zhang T., Inesta-Vaquera F., Niepel M., Zhang J., Ficarro S.B., Machleidt T., Xie T., Marto J.A., Kim N., Sim T., et al. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 2012, 19:140-154.
53. Zuber J., Radtke I., Pardee T.S., Zhao Z., Rappaport A.R., Luo W., McCurrach M.E., Yang M.M., Dolan M.E., Kogan S.C., et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009, 23:877-889.